Alpha Cognition Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 40% sequential revenue growth, strong prescriber and facility adoption, and expanded clinical and commercial initiatives. Operating loss increased due to deliberate investment, but the company remains on track for 2027 profitability and maintains a strong cash position.
Fiscal Year 2025
-
ZUNVEYL adoption accelerated in Q4 2025, with strong sales growth, expanding prescriber base, and improved payer access. The company remains well-funded, expects continued growth in 2026, and is advancing key clinical studies to further differentiate its product.
-
The discussion highlighted ZUNVEYL's commercial progress in the long-term care Alzheimer's market, with expanding payer coverage, robust clinical trial plans, and new formulations targeting unmet needs. Key catalysts include inflection in sales by mid-2026, international approvals, and pivotal trial data.
-
Q3 2025 saw robust ZUNVEYL sales growth, expanded long-term care engagement, and improved financials, with a strengthened balance sheet and reduced expense guidance. Market access and prescriber adoption accelerated, supported by new studies and strategic pricing actions.
-
ZUNVEYL, a newly FDA-approved Alzheimer's drug, launched in April 2024 with a focus on the U.S. long-term care market, showing strong early adoption and superior tolerability. The company targets profitability by 2027, is expanding its pipeline, and anticipates significant market share growth.
-
Q2 2025 marked the first earnings post-ZUNVEYL launch, with $1.7M in revenue and strong early adoption in long-term care. Operating loss rose to $5.7M, but liquidity remains solid at $39.4M. Market access expanded, and ex-U.S. growth is on track for late 2026.
-
First quarter marked by ZUNVEYL's commercial launch, strong early adoption in long-term care, and improved financials with reduced losses and a debt-free balance sheet. Positive market feedback, minimal payer restrictions, and robust liquidity support continued growth.
-
ZUNVEYL is set for a March launch in the $2B long-term care Alzheimer's market, offering improved tolerability and efficacy over current treatments. The commercial team is nearly fully staffed, pricing is set at $749/month, and the company targets break-even in three years.
Fiscal Year 2024
-
Reported strong liquidity after a $52M capital raise and NASDAQ cross-listing, with ZUNVEYL's U.S. launch showing positive early demand and prescriber feedback. 2024 net loss increased to $14.6M, but cash is expected to support break-even by year three if sales and expense targets are met.